ed CYP3A4 substrates in which a decreased effect would be undesirable. The effect of siltuximab on CYP450 enzyme activity can persist for several weeks after stopping therapy.
Intravenous Route
After siltuximab administration, once every 3 weeks, the Cmax occurred close to the end of the infusion. At steady state, the mean Cmax is 332 mcg/ml (42% CV) and the mean predose trough concentration is 84 mcg/ml (78% CV). With the once every 3 dose regimen, steady state is achieved by the sixth infusion and siltuximab accumulates approximately 1.7-fold relative to a single dose. After multiple doses, siltuximab showed approximately dose proportional pharmacokinetics over the dose range of 2.8—11 mg/kg. |
